Lucía Gómez-Pérez

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China ashpublications.org/blood/article-… The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years, respectively. #HLH @BloodPortfolio

Excited to share our latest study in @BloodCancerJnl! We’ve validated the AlloHCT-refined #ELN2022 risk classification for AML patients undergoing AlloHCT spotlighting the high‐risk Adv-Plus group Thanks to all authors from @GETH_info for their help. nature.com/articles/s4140…

📸 #FotoDeGrupo #gesmd2025 Un encuentro con un nivel de ponencias excepcional.👏Enhorabuena a las coordinadoras, Mar Tormo y Patricia Font y a todos los ponentes. Seguimos a las 15:00h 👉NEOPLASIAS MIELOIDES ASOCIADAS A PREDISPOSICIÓN EN LÍNEA GERMINAL Y FALLO MEDULAR @sehh_es

🎯The best of #ASH25 for MDS by the best of us @FelixLCadenas

🔝 Magistral intervención de @Santin13Valeria, de la Universidad de Florencia, sobre el manejo del #SMD de bajo riesgo y la incorporación de los nuevos #fármacos. #gesmd #HematoEnRed @sehh_es

Finally out!!! Outcomes of 1000 intensively treated 18-70yrs #AML, we depict why less than 50% non-fav pts reach alloHCT in CR1, ICSA score can help orienting treatment plan at diagnosis. @hematosantpau @grupoCETLAM @BloodCancerJnl #citeas" target="_blank" rel="nofollow noopener">nature.com/articles/s4140…

Excited to share our first 2025 publication addressing a critical gap by exploring allo-HCT outcomes in geriatric patients, a historically underrepresented group in clinical trials due to toxicity and mortality concerns. @ASTCT_Journal @MoffittNews sciencedirect.com/science/articl…

How I treat ETP-ALL in children ashpublications.org/blood/article-… #leusm

🍽️

CONGRESS | #ASH24 | EDUCATIONAL PRESENTATION Courtney D. DiNardo, @MDAndersonNews, discusses mutation- and MRD-informed decisions and recent advancements in the treatment of older transplant-ineligible patients with AML. She highlights that while venetoclax has markedly improved outcomes in this population, understanding its resistance mechanisms is also important for identifying patient subgroups with inferior outcomes. Treatments including IDH1, IDH2, FLT3, and menin inhibitors, alongside HMA-VEN based regimens, show promise for improving outcomes in specific patient subgroups. Follow our live feed for more updates: loom.ly/o2oK2qI #AMLsm #leusm #MedicalCongress

Look at our poster #2084 reporting the CAR-HEMATOTOX predictive results in our cohort of 58 adult patients with ALL treated at @hematoclinicbcn with #ARI0001 (var-cel). See you there at 5:30 pm (PT)!

Happy to share our comprehensive study on non-hematologic autoinmune disorders in CLL patients at #ASH24 Expansion of IL-17-F producing cells mediated by IL23 may explain lower risk of leukemic progression. Come to discuss our results at 5:30pm 🙂

Really happy to have presented @ASH_hematology 2024 two oral presentations on behalf of the @GETH_info and @grupoCETLAM about the AlloHCT Refined ELN 2022 Risk Classification validation and the prognostic value of MRD in AML patients treated with VenHMA @hematoclinicbcn

Proud of thesis defense of Marta Lafuente at UPF. Excellent presentation and up to date in Tumor mutational burden in follicular lymphoma. #lymphoma ⁦@ant_salar⁩

Interesantes conclusiones sobre el impacto de la RCH en los pacientes con TE. Gran trabajo, @martaa_st 👏🏽#Hemato2024

En sesión de tarde, la Dra. Nadal nos ha explicado la utilidad de las pruebas genéticas en la neutropenia asociada al gen ACKR1 en una población multicultural. Enhorabuena Clara! @Hemato_Mar #hemato2024

Wonderful talk of Beatriz Bellosillo PHD about molecular diagnosis of MPNs at ⁦@sehh_es⁩ @ant_salar

🎯Aspectos citologicos de las neplasias mieloides con mut TP53. #Hemato2024